From Yahoo Finance: 2025-06-07 14:38:00

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw a 20.13% increase in share prices on Friday to $5.49 with the launch of Boltz-2, an AI model predicting binding affinity. Powered by NVIDIA, it surpasses existing models like AlphaFold3 and Boltz-1 in biomolecular structure prediction.

Chief Commercial Officer Najat Khan highlighted Boltz-2’s ability to predict molecular structure and binding affinity simultaneously, aiding R&D teams in selecting promising compounds efficiently. RXRX ranks 2nd among Friday’s top stocks, but other AI investments may offer higher returns. For an inexpensive AI stock with potential benefits from Trump tariffs, check out the report.



Read more at Yahoo Finance: Why Recursion Pharmaceuticals (RXRX) Soared On Friday